TABLE OF CONTENTS
1 INTRODUCTION 41
1.1 OBJECTIVES OF THE STUDY 41
1.2 MARKET DEFINITION 41
1.3 OVERVIEW OF GLOBAL ANTICOAGULATION THERAPY MARKET 42
1.4 LIMITATIONS 43
1.5 MARKETS COVERED 43
2 MARKET SEGMENTATION 47
2.1 MARKETS COVERED 47
2.2 GLOBAL ANTICOAGULATION THERAPY MARKET: GEOGRAPHICAL SCOPE 48
2.3 YEARS CONSIDERED FOR THE STUDY 49
2.4 CURRENCY AND PRICING 49
2.5 DBMR TRIPOD DATA VALIDATION MODEL 50
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 53
2.7 DBMR MARKET POSITION GRID 54
2.8 DBMR VENDOR SHARE ANALYSIS 55
2.9 MULTIVARIATE MODELING 56
2.10 PRODUCTS LIFELINE CURVE 56
2.11 SECONDARY SOURCES 57
2.12 ASSUMPTIONS 57
3 MARKET OVERVIEW 58
3.1 DRIVERS 60
3.1.1 RISING PREVALENCE OF VENOUS THROMBOEMBOLISM AND PULMONARY EMBOLISM 60
3.1.2 INCREASING USAGE OF NOACS AS ALTERNATIVES TO WARFARIN 61
3.1.3 GROWING NUMBER OF SURGERIES 61
3.1.4 NUMBER OF PATIENTS REQUIRING LIFELONG ANTICOAGULATION THERAPY 62
3.2 RESTRAINTS 63
3.2.1 INCREASING GOVERNMENT RESTRICTION 63
3.2.2 PRODUCT RECALLS 63
3.2.3 HIGH COST OF DRUG DEVELOPMENT 64
3.3 OPPORTUNITIES 65
3.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS 65
3.3.2 INCREASING DEVELOPMENTS IN BIOENGINEERING: 65
3.4 CHALLENGES 66
3.4.1 PATENT EXPIRY 66
3.4.2 SIDE-EFFECTS OF HEPARIN 66
4 EXECUTIVE SUMMARY 67
5 PREMIUM INSIGHTS 71
6 GLOBAL ANTICOAGULATION THERAPY MARKET, BY PIPELINE ANALYSIS 73
6.1 OVERVIEW 73
7 GLOBAL ANTICOAGULATION THERAPY MARKET, BY TREATMENT 104
7.1 OVERVIEW 105
7.2 DEEP VEIN THROMBOSIS (DVT) 106
7.3 PULMONARY EMBOLISM (PE) 107
7.4 ARTERIAL THROMBOEMBOLISM (AT) 108
7.5 STROKE 109
7.6 OTHERS 110
8 GLOBAL ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS 111
8.1 OVERVIEW 112
8.2 NOVEL ORAL ANTICOAGULANTS (NOAC) 113
8.2.1 FACTOR XA INHIBITORS 114
8.2.2 DIRECT THROMBIN INHIBITORS 114
8.2.3 ANTITHROMBIN PROTEIN THERAPEUTICS 114
8.3 HEPARIN 115
8.3.1 UNFRACTIONATED HEPARIN 116
8.3.2 LOW MOLECULAR WEIGHT HEPARINS (LMWH) 116
8.3.3 ULTRA LOW MOLECULAR WEIGHT HEPARINS (ULMWH) 116
8.4 VITAMIN K ANTAGONISTS 116
8.4.1 WARFARIN 117
8.4.2 COUMARINS 117
8.5 OTHERS 118
9 GLOBAL ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE 119
9.1 OVERVIEW 120
9.2 BIVALIRUDIN 121
9.3 DABIGATRAN 122
9.4 EDOXABAN 123
9.5 BETRIXABAN 124
9.6 RIVAROXABAN 125
9.7 APIXABAN 126
9.8 ENOXAPARIN 127
9.9 DALTEPARIN 128
9.10 OTHERS 129
10 GLOBAL ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION 130
10.1 OVERVIEW 131
10.2 ORAL 132
10.3 INJECTABLE 133
10.3.1 SUBCUTENEOUS 134
10.3.2 INTRAVENOUS 134
10.3.3 INTRAPERITONEAL 134
10.3.4 OTHERS 134
11 GLOBAL ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA 135
11.1 OVERVIEW 136
11.2 CARDIOVASCULAR DISEASES 137
11.2.1 CORONARY ARTERY DISEASES 138
11.2.2 MYOCARDIAL INFARCTION 138
11.2.3 CARDIAC ARRHYTHMIA 138
11.3 ONCOLOGY 138
11.4 RESPIRATORY 139
11.5 NEPHROLOGY 140
11.6 CNS 141
11.7 OTHERS 142
12 GLOBAL ANTICOAGULATION THERAPY MARKET, BY PROCEDURE 143
12.1 OVERVIEW 144
12.2 PRE-SURGICAL PROCEDURES 145
12.3 POST SURGICAL PROCEDURES 146
12.4 KIDNEY DIALYSIS 147
12.5 HEART VALVE REPLACEMENT 148
13 GLOBAL ANTICOAGULATION THERAPY MARKET, BY TYPE 149
13.1 OVERVIEW 150
13.2 GENERICS 151
13.3 BRANDED 152
13.3.1 ELIQUIS 153
13.3.2 XARELTO 153
13.3.3 PRADAXA 153
13.3.4 LOVENOX 153
13.3.5 OTHERS 153
?
14 GLOBAL ANTICOAGULATION THERAPY MARKET, BY END USER 154
14.1 OVERVIEW 155
14.2 HOSPITALS 156
14.3 CLINICS 157
14.4 HOMECARE 158
14.5 AMBULATORY SURGICAL CENTERS 159
14.6 OTHERS 159
15 GLOBAL ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL 160
15.1 OVERVIEW 161
15.2 HOSPITAL PHARMACY 162
15.3 RETAIL PHARMACY 163
15.4 ONLINE PHARMACIES 163
16 GLOBAL ANTICOAGULATION THERAPY MARKET, BY GEOGRAPHY 165
16.1 OVERVIEW 166
16.2 NORTH AMERICA 171
16.2.1 U.S. 178
16.2.2 CANADA 182
16.2.3 MEXICO 186
16.3 EUROPE 191
16.3.1 GERMANY 198
16.3.2 FRANCE 202
16.3.3 ITALY 206
16.3.4 U.K. 210
16.3.5 SPAIN 214
16.3.6 SWITZERLAND 218
16.3.7 RUSSIA 222
16.3.8 NETHERLANDS 226
16.3.9 BELGIUM 230
16.3.10 TURKEY 234
16.3.11 REST OF EUROPE 238
16.4 ASIA-PACIFIC 239
16.4.1 JAPAN 247
16.4.2 CHINA 252
16.4.3 SOUTH KOREA 257
16.4.4 INDIA 262
16.4.5 AUSTRALIA 267
16.4.6 SINGAPORE 272
16.4.7 THAILAND 277
16.4.8 MALAYSIA 282
16.4.9 INDONESIA 287
16.4.10 PHILIPPINES 292
16.4.11 REST OF ASIA-PACIFIC 296
16.5 SOUTH AMERICA 297
16.5.1 BRAZIL 304
16.5.2 REST OF SOUTH AMERICA 308
16.6 MIDDLE EAST AND AFRICA 309
16.6.1 SOUTH AFRICA 317
16.6.2 REST OF MIDDLE EAST AND AFRICA 321
17 GLOBAL ANTICOAGULATION THERPAY MARKET, COMPANY LANDSCAPE 322
17.1 COMPANY SHARE ANALYSIS: GLOBAL 322
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 323
17.3 COMPANY SHARE ANALYSIS: EUROPE 324
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 325
18 SWOT ANALYSIS 326
18.1 STRENGTH 326
18.1.1 SIGNIFICANT INCREASE IN SHARES IN THE MARKET-FOCUSED SEGMENT 326
18.1.2 ESTABLISHED PRESENCE IN MARKET 326
18.2 WEAKNESS 327
18.2.1 DEPENDENCY ON THIRD-PARTY SUPPLIER 327
18.3 OPPORTUNITY 327
18.3.1 STRATEGIC INVESTMENTS /ACQUISITION/ PARTNERSHIPS / PRODUCT LAUNCH/ APPROVALS 327
18.4 THREAT 328
18.4.1 COMPLEXITY AND STRINGENT REQUIREMENTS FOR THE DRUG APPROVAL 328
18.5 DATA BRIDGE MARKET RESEARCH ANALYSIS 329
19 COMPANY PROFILES 330
19.1 BRISTOL-MYERS SQUIBB COMPANY 330
19.1.1 COMPANY SNAPSHOT 330
19.1.2 REVENUE ANALYSIS 330
19.1.3 COMPANY SHARE ANALYSIS 331
19.1.4 GEOGRAPHICAL PRESENCE 331
19.1.5 PRODUCT PORTFOLIO 332
19.1.6 RECENT DEVELOPMENT 332
?
19.2 PFIZER INC. 333
19.2.1 COMPANY SNAPSHOT 333
19.2.2 REVENUE ANALYSIS 333
19.2.3 COMPANY SHARE ANALYSIS 334
19.2.4 GEOGRAPHICAL PRESENCE 334
19.2.5 PRODUCT PORTFOLIO 335
19.2.6 RECENT DEVELOPMENTS 336
19.3 BAYER AG 337
19.3.1 COMPANY SNAPSHOT 337
19.3.2 REVENUE ANALYSIS 337
19.3.3 COMPANY SHARE ANALYSIS 338
19.3.4 GEOGRAPHICAL PRESENCE 338
19.3.5 PRODUCT PORTFOLIO 339
19.3.6 RECENT DEVELOPMENTS 339
19.4 JOHNSON & JOHNSON SERVICES, INC. 340
19.4.1 COMPANY SNAPSHOT 340
19.4.2 REVENUE ANALYSIS 340
19.4.3 COMPANY SHARE ANALYSIS 341
19.4.4 GEOGRAPHICAL PRESENCE 341
19.4.5 PRODUCT PORTFOLIO 342
19.4.6 RECENT DEVELOPMENTS 342
19.5 SANOFI 343
19.5.1 COMPANY SNAPSHOT 343
19.5.2 REVENUE ANALYSIS 343
19.5.3 COMPANY SHARE ANALYSIS 344
19.5.4 GEOGRAPHICAL PRESENCE 344
19.5.5 PRODUCT PORTFOLIO 345
19.5.6 RECENT DEVELOPMENT 345
19.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 346
19.6.1 COMPANY SNAPSHOT 346
19.6.2 REVENUE ANALYSIS 346
19.6.3 GEOGRAPHICAL PRESENCE 347
19.6.4 PRODUCT PORTFOLIO 347
19.6.5 RECENT DEVELOPMENT 348
19.7 ASPEN HOLDINGS 349
19.7.1 COMPANY SNAPSHOT 349
19.7.2 REVENUE ANALYSIS 349
19.7.3 GEOGRAPHICAL PRESENCE 350
19.7.4 PRODUCT PORTFOLIO 350
19.7.5 RECENT DEVELOPMENTS 351
19.8 CIPLA INC. 352
19.8.1 COMPANY SNAPSHOT 352
19.8.2 REVENUE ANALYSIS 352
19.8.3 GEOGRAPHICAL PRESENCE 353
19.8.4 PRODUCT PORTFOLIO 353
19.8.5 RECENT DEVELOPMENT 354
19.9 DAIICHI SANKYO COMPANY, LIMITED 355
19.9.1 COMPANY SNAPSHOT 355
19.9.2 REVENUE ANALYSIS 355
19.9.3 GEOGRAPHICAL PRESENCE 356
19.9.4 PRODUCT PORTFOLIO 356
19.9.5 RECENT DEVELOPMENTS 357
19.10 EAGLE PHARMACEUTICALS, INC. 358
19.10.1 COMPANY SNAPSHOT 358
19.10.2 REVENUE ANALYSIS 358
19.10.3 PRODUCT PORTFOLIO 358
19.10.4 RECENT DEVELOPMENT 358
19.11 EISAI CO., LTD. 359
19.11.1 COMPANY SNAPSHOT 359
19.11.2 REVENUE ANALYSIS 359
19.11.3 GEOGRAPHICAL PRESENCE 360
19.11.4 PRODUCT PORTFOLIO 360
19.11.5 RECENT DEVELOPMENT 360
19.12 ENDO PHARMACEUTICALS INC. 361
19.12.1 COMPANY SNAPSHOT 361
19.12.2 REVENUE ANALYSIS 361
19.12.3 GEOGRAPHICAL PRESENCE 362
19.12.4 PRODUCT PORTFOLIO 362
19.12.5 RECENT DEVELOPMENT 363
19.13 F. HOFFMANN-LA ROCHE LTD 364
19.13.1 COMPANY SNAPSHOT 364
19.13.2 REVENUE ANALYSIS 364
19.13.3 GEOGRAPHICAL PRESENCE 365
19.13.4 PRODUCT PORTFOLIO 365
19.13.5 RECENT DEVELOPMENT 365
19.14 FRESENIUS KABI AG 366
19.14.1 COMPANY SNAPSHOT 366
19.14.2 REVENUE ANALYSIS 366
19.14.3 GEOGRAPHICAL PRESENCE 367
19.14.4 PRODUCT PORTFOLIO 367
19.14.5 RECENT DEVELOPMENTS 368
19.15 HIKMA PHARMACEUTICALS PLC 369
19.15.1 COMPANY SNAPSHOT 369
19.15.2 REVENUE ANALYSIS 369
19.15.3 GEOGRAPHICAL PRESENCE 370
19.15.4 PRODUCT PORTFOLIO 370
19.15.5 RECENT DEVELOPMENT 371
19.16 MITSUBISHI TANABE PHARMA CORPORATION. 372
19.16.1 COMPANY SNAPSHOT 372
19.16.2 REVENUE ANALYSIS 372
19.16.3 GEOGRAPHICAL PRESENCE 373
19.16.4 PRODUCT PORTFOLIO 373
19.16.5 RECENT DEVELOPMENT 373
19.17 MYLAN N.V. 374
19.17.1 COMPANY SNAPSHOT 374
19.17.2 REVENUE ANALYSIS 374
19.17.3 GEOGRAPHICAL PRESENCE 375
19.17.4 PRODUCT PORTFOLIO 375
19.17.5 RECENT DEVELOPMENTS 376
19.18 NOVARTIS AG 377
19.18.1 COMPANY SNAPSHOT 377
19.18.2 REVENUE ANALYSIS 377
19.18.3 GEOGRAPHICAL PRESENCE 378
19.18.4 PRODUCT PORTFOLIO 378
19.18.5 RECENT DEVELOPMENT 379
19.19 PORTOLA PHARMACEUTICALS, INC. 380
19.19.1 COMPANY SNAPSHOT 380
19.19.2 REVENUE ANALYSIS 380
19.19.3 PRODUCT PORTFOLIO 381
19.19.4 RECENT DEVELOPMENT 381
19.20 SHANGHAI FOSUN PHARMACEUTICAL (GROUP?CO. LTD. 382
19.20.1 COMPANY SNAPSHOT 382
19.20.2 REVENUE ANALYSIS 382
19.20.3 GEOGRAPHICAL PRESENCE 383
19.20.4 PRODUCT PORTFOLIO 383
19.20.5 RECENT DEVELOPMENT 385
?
19.21 TARO PHARMACEUTICAL INDUSTRIES LTD. 386
19.21.1 COMPANY SNAPSHOT 386
19.21.2 REVENUE ANALYSIS 386
19.21.3 GEOGRAPHICAL PRESENCE 387
19.21.4 PRODUCT PORTFOLIO 387
19.21.5 RECENT DEVELOPMENT 387
19.22 TEVA PHARMACEUTICAL INDUSTRIES LTD. 388
19.22.1 COMPANY SNAPSHOT 388
19.22.2 REVENUE ANALYSIS 388
19.22.3 GEOGRAPHICAL PRESENCE 389
19.22.4 PRODUCT PORTFOLIO 389
19.22.5 RECENT DEVELOPMENTS 390
20 REFERENCES 391
21 QUESTIONNAIRE 394
22 RELATED REPORTS 40